[1]
Sau, D.K.; Butcher, R.J.; Chaudhuri, S.; Saha, N. Spectroscopic, structural and antibacterial properties of copper(II) complexes with bio-relevant 5-methyl-3- formylpyrazole N(4)-benzyl-N(4)-methylthiosemicarbazone. Mol. Cell. Biochem., 2003, 253, 21-29.
[2]
Pelosi, G. Thiosemicarbazone metal complexes: From structure to activity. Open Crystallogr. J., 2010, 3, 16-28.
[3]
Dilović, I.; Rubcić, M.; Vrdoljak, V.; Pavelić, S.K.; Kralj, M.; Piantanida, I.; Cindrić, M. Novel 11 thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and 12 structural properties, DNA interactions and antiproliferative activity. Bioorg. Med. Chem., 2008, 16, 5189-5198.
[4]
Kovacevic, Z.; Chikhani, S.; Lui, G.Y.; Sivagurunathan, S.; Richardson, D.R. The iron-15 regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the 16 PI3K and Ras signaling pathways. Antioxid. Redox Signal., 2013, 10, 874-887.
[5]
Heiner, G.G.; Fatima, N.; Russell, P.K.; Haase, A.T.; Ahmad, N.; Mohammed, N.; Thomas, D.B.; Mack, T.M.; Khan, M.M.; Knatterud, G.L.; Anthony, R.L.; McCrumb, F.R., Jr Field trials 19 of methisazone as a prophylactic agent against smallpox. Am. J. Epidemiol., 1971, 94, 435-449.
[6]
Jutten, P.; Schumann, W.; Hartl, A.; Dahse, H.M.; Grafe, U. Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J. Med. Chem., 2007, 50, 3661-3666.
[7]
Yogeeswari, P.; Sriram, D.; Thirumurugan, R.; Raghavendran, J.V.; Sudhan, K.; Pavana, R.K.; Stables, J. Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: Hybrid pharmacophore-based design. J. Med. Chem., 2005, 48, 6202-6211.
[8]
Greenbaum, D.C.; Mackey, Z.; Hansell, E.; Doyle, P.; Gut, J.; Caffrey, C.R.; Lehrman, J.; Rosenthal, P.J.; McKerrow, J.H.; Chibale, K. Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem., 2004, 47, 3212-3219.
[9]
Neve, R.M.; Chin, K.; Fridlyand, J.; Yeh, J.; Baehner, F.L.; Fevr, T.; Clark, L.; Bayani, N.; Coppe, J.P.; Tong, F.; Speed, T.; Spellman, P.T.; DeVries, S.; Lapuk, A.; Wang, N.J.; Kuo, W.L.; Stilwell, J.L.; Pinkel, D.; Albertson, D.G.; Waldman, F.M.; McCormick, F.; Dickson, R.B.; Johnson, M.D.; Lippman, M.; Ethier, S.; Gazdar, A.; Gray, J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006, 10, 515-527.
[10]
Chen, J.; Huang, Y.W.; Liu, G.; Afrasiabi, Z.; Sinn, E.; Padhye, S.; Ma, Y. The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol. Appl. Pharmacol., 2004, 197, 40-48.
[11]
Li, J.; Zheng, L.M.; King, I.; Doyle, T.W.; Chen, S.H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr. Med. Chem., 2001, 2, 121-133.
[12]
Finch, R.A.; Liu, M.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent 34 inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 2000, 59, 983-991.
[13]
Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective 3 identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100, 39834-3988.
[14]
Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA, 2004, 101, 781-786.
[15]
Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res., 2005, 65, 6207-6219.
[16]
Al-Hajj, M.; Becker, M.W.; Wicha, M.; Weissman, I.; Clarke, M.F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev., 2004, 14, 43-47.
[17]
Bhat, M.A.; Al-Dhfyan, A.; Al-Omar, M.A. Targeting Cancer Stem Cells with Novel 4-(4-2 substituted phenyl)-5-(3,4,5-trimethoxy/ 3,4-dimethoxy)-3 benzoyl-3,4-dihydropyrimidine-2(1H)-one/thiones. Molecules, 2016, 21, 1746-1755.
[18]
Naglah, A.M.; Shinwari, Z.; Bhat, M.A.; Al-Tahhan, M.; Al-Omar, M.A. Al- Dhfyan, A. Targeting leukemic side population cells by isatin derivatives of nicotinic acid amide. J. Biol. Regul. Homeost. Agents, 2016, 30, 624-628.
[19]
Bhat, M.A.; Al-Dhfyan, A.; Khan, A.A.; Al-Harbi, N.; Manogaran, P.S.; Alanazi, A.M.; Fun, H.K.; Al-Omar, M.A. Targeting HER-2 over expressed breast cancer cells with 2-cyclohexyl-N-[(Z)-(substituted phenyl/furan-2-yl/thiophene-2-yl)methylidene]hydra-zinecarbothioamide. Bioorg. Med. Chem. Lett., 2015, 25, 83-87.
[20]
Bhat, M.A.; Al-Dhfyan, A.; Naglah, A.M.; Khan, A.A.; Al-Omar, M.A. Lead optimization of 2-cyclohexyl-N-[(Z)-(3-methoxyphenyl/ 3-hydroxyphenyl) methylidene] hydrazinecarbothioamide for targeting HER-2 over expressed breast cancer cell line SKBr-3. Molecules, 2015, 20, 18246-18263.
[21]
Hu, W.X.; Zhou, W.; Xia, C.N.; Wen, X. Synthesis and anticancer activity of thiosemicarbazones. Bioorg. Med. Chem. Lett., 2006, 16, 2213-2218.
[22]
Cunha, S. da Silva, T.L. One-pot and catalyst-free synthesis of thiosemicarbazones via multicomponent coupling reactions. Tetrahedron Lett., 2009, 50, 2090-2093.
[23]
Dilović, I.; Rubcić, M.; Vrdoljak, V.; Kraljević, P.S.; Kralj, M.; Piantanida, I.; Cindrić, M. Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity. Bioorg. Med. Chem., 2008, 16, 5189-5198.
[24]
Eldehna, W.M.; Almahli, H.; Al-Ansary, G.H.; Ghabbour, H.A.; Aly, M.H.; Ismael, O.E.; Al-Dhfyan, A.; Abdel-Aziz, H.A. Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. J. Enzyme Inhib. Med. Chem., 2017, 32, 600-613.
[25]
Abdel-Aziz, H.A.; Elsaman, T.; Al-Dhfyan, A.; Attia, M.I.; Al-Rashood, K.A.; Al-Obaid, A.R. Synthesis and anticancer potential of certain novel 2-oxo-N'-(2-oxoindolin-3-ylidene)-2H-chromene-3-carbohydrazides. Eur. J. Med. Chem., 2013, 70, 358-363.